4DMedical targets US$2.5B PE market entry for CTVQ
Filed with ASX · · 3 pages · English
Summary by 6ix AI
4DMedical Ltd. has announced the launch of the CLEAR clinical evidence program aimed at facilitating the entry of its CT:VQ technology into the acute pulmonary embolism market, which is valued at a significant amount in the U.S. The program includes a multi-centre study comparing CT:VQ with the current standard imaging method for suspected pulmonary embolism, CTPA, and has secured a clinical research agreement with Mass General Brigham as the lead site. This initiative is expected to expand the obtainable market for CT:VQ in the U.S. substantially, enhancing the company's growth prospects in the medical imaging sector.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from 4DMedical
- 4DMedical creates EU platform via contextflow acquisition
- CTVQ enters US Outpatient Market via SimonMed 170 sites
- Major publication validates CTVQ for lung surgery
- GSK contract, UK clearance for CTVQ, and ASX 200 inclusion
- Insignia Financial to be removed from the S&P/ASX 200 Index
Later from 4DMedical
- 4DMedical receives TGA approval for CTVQ in Australia
- 4DMedical Receives TGA Approval for CT: VQ™, Bringing Non-Contrast Ventilation-Perfusion Imaging to Australia
- Pause in trade
- US Bill directs VA to adopt 4D lung imaging
- Quarterly Activity Report and Appendix 4C
Follow 4DMedical into a list and get an email when it puts out news.
Follow 4DMedical